DGIdb - AEE-788 Drug Record

AEE-788 chembl:CHEMBL587723 Antineoplastic

Alternate Names:

NVP-AEE-788
AEE-788
AEE788
NVP-AEE788
GNF-PF-5343
AEE 788

Drug Info:

Drug Class	Kinase Inhibitors

(2 More Sources)

Publications:

Kancha et al., 2011, Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib., PLoS ONE
Kancha et al., 2009, Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy., Clin. Cancer Res.

AEE-788 ERBB2

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical

PMIDs:
22046346

Sources:
JAX-CKB MyCancerGenome GuideToPharmacology ChemblInteractions
AEE-788 EGFR

Interaction Score: 0.22

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type resistant

Approval Status Preclinical

PMIDs:
19147750

Sources:
JAX-CKB MyCancerGenome GuideToPharmacology ChemblInteractions
AEE-788 ERBB4

Interaction Score: 0.2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
GuideToPharmacology
AEE-788 KDR

Interaction Score: 0.16

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
MyCancerGenome GuideToPharmacology ChemblInteractions
AEE-788 FGFR2

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
AEE-788 FGFR3

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
AEE-788 FLT1

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor receptor 1 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

MyCancerGenome: AEE788
- Version: 20-Jun-2017
Alternate Names:

NVP-AEE788 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:

JAX-CKB: AEE788

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Kancha et al., 2011, Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib., PLoS ONE

Kancha et al., 2009, Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy., Clin. Cancer Res.

TTD: AEE-788
- Version: 2020.06.01
Alternate Names:

D0G2QH TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL587723
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL587723
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
GuideToPharmacology: 223365978
- Version: 29-September-2020
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	Advanced Solid Tumor
Response Type	sensitive
Approval Status	Preclinical

Direct Interaction?	False
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

Mechanism of Interaction	Vascular endothelial growth factor receptor 1 inhibitor
Direct Interaction	yes

AEE-788 Drug Record

AEE-788 chembl:CHEMBL587723 Antineoplastic

Alternate Names:

Drug Info:

Publications:

AEE-788 ERBB2

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type sensitive Approval Status Preclinical

PMIDs: 22046346

Sources: JAX-CKB MyCancerGenome GuideToPharmacology ChemblInteractions

AEE-788 EGFR

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type resistant Approval Status Preclinical

PMIDs: 19147750

Sources: JAX-CKB MyCancerGenome GuideToPharmacology ChemblInteractions

AEE-788 ERBB4

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: None found

Sources: GuideToPharmacology

AEE-788 KDR

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: MyCancerGenome GuideToPharmacology ChemblInteractions

AEE-788 FGFR2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

AEE-788 FGFR3

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

AEE-788 FLT1

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Vascular endothelial growth factor receptor 1 inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

MyCancerGenome: AEE788

Alternate Names: NVP-AEE788 Development Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

JAX-CKB: AEE788

Alternate Names:

Drug Info:

Publications: Kancha et al., 2011, Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib., PLoS ONE Kancha et al., 2009, Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy., Clin. Cancer Res.

TTD: AEE-788

Alternate Names: D0G2QH TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL587723

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL587723

Alternate Names:

Drug Info:

Publications:

GuideToPharmacology: 223365978

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical

PMIDs:
22046346

Sources:
JAX-CKB MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type resistant

Approval Status Preclinical

PMIDs:
19147750

Sources:
JAX-CKB MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Vascular endothelial growth factor receptor 1 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Alternate Names:

NVP-AEE788 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:

Kancha et al., 2011, Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib., PLoS ONE

Kancha et al., 2009, Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy., Clin. Cancer Res.

Alternate Names:

D0G2QH TTD Drug ID